[1].Partridge A, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13).2022 SABCS. GS4-09....
参考文献: [1].Partridge A, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13).2022 SABCS. GS4-09. [2].Ruggeri M, Pagan E, Bagnardi V, ...
1. Azim HA, Niman SM, Partridge AH, et al. Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy results from the POSITIVE trial. Presented at the 2024 European Society for Medical Oncology Congress (ESMO);...
1、Partridge AH,Niman SM,Ruggeri M,et al.for the International Breast Cancer Study Group,and the POSITIVE Trial Collaborators.Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.N Engl J Med 2023;388:1645-1656. 2、Giordano SH.POSITIVE Results for Breast Cancer Survivors Who Des...
1、Partridge AH,Niman SM,Ruggeri M,et al.for the International Breast Cancer Study Group,and the POSITIVE Trial Collaborators.Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.N Engl J Med 2023;388:1645-1656. 2、Giordano SH.POSITIVE Results for Breast Cancer Survivors Who Des...
McNamee D. High dose chemotherapy positive in breast cancer trial. Lancet 2000;355:1973.D. McNamee, High dose chemotherapy positive in breast cancer trial, Lancet 355 (2000) 1973.McNamee D. High dose chemotherapy positive in breast cancer trial [abstract]. Lancet. 2000;355:1973....
Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China. ...
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9–20 (2022). A phase III trial that demonstrated the efficacy of the anti-HER2 ADC, trastuzumab deruxtecan, in HER2-low metastatic breast cancer. Article CAS Google Scholar Baselga, J....
Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic ...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, ner